{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:19Z","timestamp":1793054659556,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004787","name":"TRC","doi-asserted-by":"publisher","award":["BFP\/RGP\/ HSS \/19\/198"],"award-info":[{"award-number":["BFP\/RGP\/ HSS \/19\/198"]}],"id":[{"id":"10.13039\/501100004787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.neuint.2021.105135","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T11:36:43Z","timestamp":1626176203000},"page":"105135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Search for safer and potent natural inhibitors of Parkinson's disease"],"prefix":"10.1016","volume":"149","author":[{"given":"Sidrah Tariq","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagheer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajmal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-5942","authenticated-orcid":false,"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2021.105135_bib1","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1523\/JNEUROSCI.0490-15.2015","article-title":"Role of striatal cholinergic interneurons in set-shifting in the rat","volume":"35","author":"Aoki","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2021.105135_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuint.2021.105135_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fnut.2018.00095","article-title":"Forestalling the epidemics of Parkinson's disease through plant-based remedies","volume":"5","author":"Banjari","year":"2018","journal-title":"Front Nutr"},{"key":"10.1016\/j.neuint.2021.105135_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","article-title":"Parkinson's disease: a review","volume":"6","author":"Beitz","year":"2014","journal-title":"Front. Biosci."},{"key":"10.1016\/j.neuint.2021.105135_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/13543784.2014.869209","article-title":"Dopamine receptor agonists for Parkinson's disease","volume":"23","author":"Blandini","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuint.2021.105135_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's disease: from pathogenesis to pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2021.105135_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: a critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuint.2021.105135_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11030-013-9490-6","article-title":"Selective MAO-B inhibitors: a lesson from natural products","volume":"18","author":"Carradori","year":"2014","journal-title":"Mol. Divers."},{"key":"10.1016\/j.neuint.2021.105135_bib9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2174\/0929867323666160106150821","article-title":"Morin: a promising natural drug","volume":"23","author":"Caselli","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson's disease in women and men: what's the difference?","volume":"9","author":"Cerri","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuint.2021.105135_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205208","article-title":"Amelioration of mitochondrial quality control and proteostasis by natural compounds in Parkinson's disease models","volume":"20","author":"Cho","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2021.105135_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1212\/WNL.0000000000004175","article-title":"Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study","volume":"89","author":"Cilia","year":"2017","journal-title":"Neurology"},{"issue":"Pt 8","key":"10.1016\/j.neuint.2021.105135_bib13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2021.105135_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejmech.2016.03.087","article-title":"Recent developments of C-4 substituted coumarin derivatives as anticancer agents","volume":"119","author":"Dandriyal","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.neuint.2021.105135_bib15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuint.2021.105135_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/jnp.12028","article-title":"Executive dysfunction in Parkinson's disease: a review","volume":"7","author":"Dirnberger","year":"2013","journal-title":"J. Neuropsychol."},{"key":"10.1016\/j.neuint.2021.105135_bib17","doi-asserted-by":"crossref","first-page":"3574012","DOI":"10.1155\/2017\/3574012","article-title":"Plants-derived neuroprotective agents: cutting the cycle of cell death through multiple mechanisms","volume":"2017","author":"Elufioye","year":"2017","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.neuint.2021.105135_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1871524919666190619090852","article-title":"Evaluation of selected natural compounds as dual inhibitors of catechol-O-methyltransferase and monoamine oxidase","volume":"19","author":"Engelbrecht","year":"2019","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib19","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/mds.27195","article-title":"Falls in Parkinson's disease: a complex and evolving picture","volume":"32","author":"Fasano","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2021.105135_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2020.03.002","article-title":"Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?","volume":"73","author":"Fothergill-Misbah","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuint.2021.105135_bib21","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1080\/07391102.2019.1699446","article-title":"Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics\/molecular mechanics and molecular dynamics simulations","volume":"38","author":"Govindasamy","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.neuint.2021.105135_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/mds.28075","article-title":"Ten unsolved questions about neuroinflammation in Parkinson's disease","volume":"36","author":"Hirsch","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2021.105135_bib23","first-page":"3219","article-title":"Recent developments of coumarin hybrids as anti-fungal agents","volume":"17","author":"Hu","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/1871524913666140109113341","article-title":"Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders","volume":"13","author":"Jatana","year":"2013","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib25","article-title":"Monoamine oxidase and dopamine \u03b2-hydroxylase inhibitors from the fruits of Gardenia jasminoides","volume":"20","author":"Jh","year":"2012","journal-title":"Biomolecules & therapeutics"},{"key":"10.1016\/j.neuint.2021.105135_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/jmf.2017.4078","article-title":"Beneficial effects of flavonoids against Parkinson's disease","volume":"21","author":"Jung","year":"2018","journal-title":"J. Med. Food"},{"key":"10.1016\/j.neuint.2021.105135_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2021.105135_bib28","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2174\/0929867325666180821153316","article-title":"Xanthine derivatives as agents affecting non-dopaminergic neuroprotection in Parkinson's disease","volume":"27","author":"Kasabova-Angelova","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/jnnp.2003.028761","article-title":"Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study","volume":"75","author":"Katzenschlager","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuint.2021.105135_bib30","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1212\/WNL.50.6_Suppl_6.S11","article-title":"Mechanism of action of dopaminergic agents in Parkinson's disease","volume":"50","author":"Koller","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2021.105135_bib31","first-page":"470","article-title":"Antibacterial activity of polyphenols of garcinia indica","volume":"73","author":"Lakshmi","year":"2011","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuint.2021.105135_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","article-title":"Epidemiology of Parkinson disease","volume":"34","author":"Lee","year":"2016","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuint.2021.105135_bib33","doi-asserted-by":"crossref","first-page":"155S","DOI":"10.1592\/phco.27.12part2.155S","article-title":"Overview of Parkinson's disease","volume":"27","author":"Lew","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuint.2021.105135_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.14336\/AD.2019.0805","article-title":"Parkinson disease and orthostatic hypotension in the elderly: recognition and management of risk factors for falls","volume":"11","author":"LeWitt","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/j.neuint.2021.105135_bib35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/cns.12727","article-title":"Adverse effects produced by different drugs used in the treatment of Parkinson's disease: a mixed treatment comparison","volume":"23","author":"Li","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuint.2021.105135_bib36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/00498254.2016.1204567","article-title":"Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites","volume":"47","author":"Liang","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuint.2021.105135_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41401-020-0380-z","article-title":"Targeting the cholinergic system in Parkinson's disease","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuint.2021.105135_bib38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/jech.2008.084954","article-title":"Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis","volume":"64","author":"Lix","year":"2010","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.neuint.2021.105135_bib39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/dmd.31.5.572","article-title":"Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate","volume":"31","author":"Lu","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuint.2021.105135_bib40","article-title":"Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: an in silico approach","volume":"25","author":"Mazumder","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.neuint.2021.105135_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mehy.2018.06.009","article-title":"Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease","volume":"117","author":"Mazumder","year":"2018","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.neuint.2021.105135_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/gerona\/glq201","article-title":"Virtual reality for gait training: can it induce motor learning to enhance complex walking and reduce fall risk in patients with Parkinson's disease?","volume":"66","author":"Mirelman","year":"2011","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.neuint.2021.105135_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchemneu.2019.01.007","article-title":"Chemical neuroanatomy of the substantia nigra in the ovine brain","volume":"97","author":"Murray","year":"2019","journal-title":"J. Chem. Neuroanat."},{"issue":"Suppl. 3","key":"10.1016\/j.neuint.2021.105135_bib44","doi-asserted-by":"crossref","first-page":"S580","DOI":"10.1002\/mds.22037","article-title":"Pharmacokinetics and pharmacodynamics of levodopa","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2021.105135_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2019.01.027","article-title":"Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors","volume":"847","author":"Pinheiro","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105135_bib46","first-page":"114","article-title":"\u201cBad guys\u201d among the antiparkinsonian drugs","volume":"21","author":"Pirtosek","year":"2009","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.neuint.2021.105135_bib47","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.neuint.2021.105135_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-198502000-00002","article-title":"Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management","volume":"5","author":"Rabkin","year":"1985","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuint.2021.105135_bib49","doi-asserted-by":"crossref","first-page":"113518","DOI":"10.1016\/j.jep.2020.113518","article-title":"Mucuna pruriens (L.) DC. seed extract inhibits lipopolysaccharide-induced inflammatory responses in BV2 microglial cells","volume":"267","author":"Rachsee","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuint.2021.105135_bib50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JPD-181500","article-title":"Mucuna pruriens combined with carbidopa in Parkinson's disease: a case report","volume":"9","author":"Radder","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuint.2021.105135_bib51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s13205-020-02532-7","article-title":"Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective","volume":"10","author":"Rai","year":"2020","journal-title":"3 Biotech"},{"key":"10.1016\/j.neuint.2021.105135_bib52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/00207454.2012.668727","article-title":"Patient perception of Levido reticularis due to amantadine","volume":"122","author":"Rana","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuint.2021.105135_bib53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0278-5846(89)90137-1","article-title":"Common side effects associated with monoamine oxidase inhibitors","volume":"13","author":"Remick","year":"1989","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2021.105135_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.disamonth.2007.05.002","article-title":"Current pharmacotherapeutic treatment options in Parkinson's disease","volume":"53","author":"Rezak","year":"2007","journal-title":"Dis Mon"},{"key":"10.1016\/j.neuint.2021.105135_bib55","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2021.105135_bib56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.colsurfb.2018.01.044","article-title":"Garcinia indica mediated biogenic synthesis of silver nanoparticles with antibacterial and antioxidant activities","volume":"164","author":"Sangaonkar","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.neuint.2021.105135_bib57","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1016\/j.bmcl.2010.05.023","article-title":"Novel coumarin derivatives as potential antidyslipidemic agents","volume":"20","author":"Sashidhara","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"14\u201316","key":"10.1016\/j.neuint.2021.105135_bib58","first-page":"20","article-title":"Parkinson's disease: making the diagnosis, selecting drug therapies","volume":"49","author":"Scharre","year":"1994","journal-title":"Geriatrics"},{"key":"10.1016\/j.neuint.2021.105135_bib59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11064-010-0289-x","article-title":"Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus Niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency","volume":"36","author":"Sengupta","year":"2011","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuint.2021.105135_bib60","first-page":"159","article-title":"[Disease-Modifying therapy for Parkinson's disease]","volume":"69","author":"Shimura","year":"2017","journal-title":"Brain Nerve"},{"key":"10.1016\/j.neuint.2021.105135_bib61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2021.105135_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","article-title":"Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia","volume":"31","author":"Stacy","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuint.2021.105135_bib63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/pcp\/pcz076","article-title":"The age of coumarins in plant\u2013microbe interactions","volume":"60","author":"Stringlis","year":"2019","journal-title":"Plant Cell Physiol."},{"key":"10.1016\/j.neuint.2021.105135_bib64","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson's disease","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.neuint.2021.105135_bib65","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuint.2021.105135_bib66","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1080\/07391102.2018.1557557","article-title":"Alizarin interaction with sickle hemoglobin: elucidation of their anti-sickling properties by multi-spectroscopic and molecular modeling techniques","volume":"37","author":"Syed","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.neuint.2021.105135_bib67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuron.2018.12.004","article-title":"Cholinergic interneurons amplify thalamostriatal excitation of striatal indirect pathway neurons in Parkinson's disease models","volume":"101","author":"Tanimura","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuint.2021.105135_bib68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-0037-1601888","article-title":"Diagnosis and management of Parkinson's disease","volume":"37","author":"Tarakad","year":"2017","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.neuint.2021.105135_bib69","article-title":"Daphnetin: a novel anti-Helicobacter pylori agent","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2021.105135_bib70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejmech.2017.09.068","article-title":"Recent advances in discovery and development of natural products as source for anti-Parkinson\u2019s disease lead compounds","volume":"141","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuint.2021.105135_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2019.02.019","article-title":"Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease","volume":"126","author":"Ztaou","year":"2019","journal-title":"Neurochem. Int."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018621001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018621001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:42:58Z","timestamp":1777527778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018621001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":71,"alternative-id":["S0197018621001819"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2021.105135","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Search for safer and potent natural inhibitors of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2021.105135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105135"}}